Literature DB >> 4007025

Phase II study of elliptinium in metastatic soft tissue sarcoma.

R Somers, J Rouësse, A van Oosterom, D Thomas.   

Abstract

A phase II study was carried out with 9-hydroxy-methyl-elliptinium (9-HME) in metastatic soft tissue sarcoma. The dose was 100 mg/m2 weekly in 1 1/2 hr intravenous infusion protected from light. Nineteen cases were evaluable for response, all previously treated with other chemotherapy regimens. No remissions were seen. Major toxicities were nausea and vomiting, dryness of the mouth and anorexia. It is concluded that 9-HME is not an effective drug in metastatic soft tissue sarcoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007025     DOI: 10.1016/0277-5379(85)90086-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  2 in total

1.  Activity of batracylin (NSC-320846) against solid tumors of mice.

Authors:  P Mucci-LoRusso; L Polin; M C Bissery; F Valeriote; J Plowman; G D Luk; T H Corbett
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

2.  Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.

Authors:  R H Earhart; D J Amato; A Y Chang; E C Borden; M Shiraki; M E Dowd; R L Comis; T E Davis; T J Smith
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.